GT Apeiron Therapeutics
http://www.apeiron-bio.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From GT Apeiron Therapeutics
Exscientia Focus Firmly On Pipeline After CEO Exit Scandal
The sacking of CEO Andrew Hopkins over inappropriate relationships with two employees has cast a cloud over the high-profile AI biotech.
BMS Opts In On Exscientia’s AI-Designed Immune-Modulating Candidate
Bristol Myers Squibb will in-license an immune-modulating drug candidate created by AI-pioneer Exscientia, the first in their expanded multi-target alliance announced in May.
Company Information
- Industry
- Pharmaceuticals
-
Digital Health
- Artificial Intelligence
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- GT Apeiron Therapeutics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GT Apeiron Therapeutics
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice